These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 12716529)

  • 21. [Vaccination against hepatitis B and epidemiological situation of this disease in European countries in the years 1990-2001].
    Magdzik W
    Przegl Epidemiol; 2006; 60(2):179-84. PubMed ID: 16964667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of a hepatitis B vaccination program in Chiang Mai, Thailand.
    Jutavijittum P; Jiviriyawat Y; Yousukh A; Hayashi S; Toriyama K
    Southeast Asian J Trop Med Public Health; 2005 Jan; 36(1):207-12. PubMed ID: 15906670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China.
    Liang X; Bi S; Yang W; Wang L; Cui G; Cui F; Zhang Y; Liu J; Gong X; Chen Y; Wang F; Zheng H; Wang F; Guo J; Jia Z; Ma J; Wang H; Luo H; Li L; Jin S; Hadler SC; Wang Y
    J Infect Dis; 2009 Jul; 200(1):39-47. PubMed ID: 19469708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prophylaxis of hepatitis type B: immunoglobulins and vaccines.
    Zuckerman AJ
    Clin Gastroenterol; 1980 Jan; 9(1):65-83. PubMed ID: 6994953
    [No Abstract]   [Full Text] [Related]  

  • 25. Influence of circadian rhythm on the efficacy of the hepatitis B vaccination.
    Karabay O; Temel A; Koker AG; Tokel M; Ceyhan M; Kocoglu E
    Vaccine; 2008 Feb; 26(9):1143-4. PubMed ID: 18255201
    [No Abstract]   [Full Text] [Related]  

  • 26. Perinatal hepatitis B transmission and vaccination timing in a managed care cohort: assessment of the temporary delay in newborn hepatitis B vaccination due to thimerosal content.
    Chang S; Begier EM; Schech SD; Venus P; Shatin D; Braun MM; Ball R
    Pediatr Infect Dis J; 2007 Apr; 26(4):329-33. PubMed ID: 17414397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integration of hepatitis B vaccination into national immunisation programmes. Alternative strategies must be considered before universal vaccination is adopted.
    Dunn J; Shukla R; Neal K
    BMJ; 1997 Jul; 315(7100):121-2. PubMed ID: 9240065
    [No Abstract]   [Full Text] [Related]  

  • 28. Hepatitis B immunization in adolescent girls.
    Bapat S; Joshi D; Naik SS; Bavdekar A; Bhave S; Pandit A
    Indian Pediatr; 2001 Oct; 38(10):1160-2. PubMed ID: 11677306
    [No Abstract]   [Full Text] [Related]  

  • 29. Prevalence of hepatitis B surface antigen in vaccinated children and controls in rural Nigeria.
    Odusanya OO; Alufohai FE; Meurice FP; Wellens R; Weil J; Ahonkhai VI
    Int J Infect Dis; 2005 May; 9(3):139-43. PubMed ID: 15840454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The first identified hepatitis B virus vaccine escape mutation in Turkey.
    Kutlu T; Soycan LY; Karatayli E; Türkyilmaz AR; Yurdaydin C; Bozdayi AM
    J Clin Virol; 2006 Feb; 35(2):201-2. PubMed ID: 16230046
    [No Abstract]   [Full Text] [Related]  

  • 31. [Increased risk of hepatitis B due to incomplete or untimely immunisation in one-quarter of infants of hepatitis-B-virus carriers].
    van der Ploeg CP; Kateman H; Vermeer-de Bondt PE; Verkerk PH
    Ned Tijdschr Geneeskd; 2004 Sep; 148(37):1820-4. PubMed ID: 15495511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seroepidemiology of hepatitis B in Greek children 6 years after the implementation of universal vaccination.
    Papaevangelou V; Hadjichristodoulou C; Cassimos DC; Pantelaki K; Tzivaras A; Hatzimichael A; Theodoridou M
    Infection; 2008 Mar; 36(2):135-9. PubMed ID: 18231718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Coverage of vaccination against hepatitis B in Poland in 2004].
    Magdzik W; Czarkowski MP
    Przegl Epidemiol; 2006; 60(2):185-92. PubMed ID: 16964668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness.
    Vimolket T; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 2005 May; 36(3):693-9. PubMed ID: 16124440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A success story: universal vaccination in Italy--what has to be done to eradicate residual acute hepatitis B?
    Gervais A; Longuet P; Leport C
    Clin Infect Dis; 2008 Mar; 46(6):876-7. PubMed ID: 18269331
    [No Abstract]   [Full Text] [Related]  

  • 36. Possible benefits of the targeting of indoleamine 2,3-dioxygenase (IDO) in hepatitis B vaccination.
    Straten PT; Andersen MH
    Vaccine; 2011 May; 29(21):3728. PubMed ID: 21420415
    [No Abstract]   [Full Text] [Related]  

  • 37. [The evaluation on immunogenicity of hepatitis B vaccine].
    Li HM; Liang ZL; Zhang HY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 May; 25(5):378-81. PubMed ID: 15231155
    [No Abstract]   [Full Text] [Related]  

  • 38. [Hepatitis B vaccination in France: vaccination coverage in 2002].
    Denis F
    Bull Acad Natl Med; 2004; 188(1):115-23. PubMed ID: 15368931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Analysis on economic efficacy regarding previous strategies and current recommendations for vaccination against hepatitis B virus in China].
    Zhang SX; Dang RB; Zhang WD; Liang XF; Cui FQ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Oct; 29(10):1003-8. PubMed ID: 19173882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A boost to hepatitis B vaccine: no need for boosters.
    Aggarwal R
    Natl Med J India; 2005; 18(6):313-4. PubMed ID: 16483032
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.